{"nctId":"NCT04556656","briefTitle":"PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD","startDateStruct":{"date":"2020-10-16","type":"ACTUAL"},"conditions":["Huntington Disease"],"count":499,"armGroups":[{"label":"Pridopidine","type":"EXPERIMENTAL","interventionNames":["Drug: Pridopidine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Pridopidine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION CRITERIA MAIN STUDY\n\n1. Diagnosis of HD based on clinical features and the presence of ≥36 CAG repeats in the huntingtin gene\n2. Diagnostic confidence level (DCL) of 4\n3. Adult-onset HD with onset of signs and symptoms ≥18 years of age\n4. Stage 1 or Stage 2 HD, defined as a UHDRS-TFC score of ≥7, at screening\n\nEXCLUSION CRITERIA\n\n1. Use of pridopidine within 12 months before the baseline visit.\n2. Gene therapy at any time\n3. Any serious medical condition or clinically significant laboratory, or vital sign abnormality that precludes the patient's safe participation in and completion of the study e.g. significant heart disease within 12 weeks before baseline or history of certain cardiac arrhythmias\n4. History of epilepsy or seizures within the last 5 years\n5. Pregnant or breastfeeding, or intention to become pregnant during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"25 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)","description":"The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \\[domestic chores, activities of daily living, finances, care level, and occupation\\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"0.119"},{"groupId":"OG001","value":"-0.95","spread":"0.119"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 65 in the UHDRS TFC Score (ITT)","description":"The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \\[domestic chores, activities of daily living, finances, care level, and occupation\\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.17","spread":"0.120"},{"groupId":"OG001","value":"-0.94","spread":"0.120"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT)","description":"The composite Unified Huntington Disease Rating Scale (cUHDRS) uses 4 components:\n\nTotal Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Higher score = worse outcome. Best score=0. Worst score= 124.\n\nStroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. Best score=100. Worst score=0.\n\nSymbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to match numbers with symbols. Scores = correct answers in 90 sec. Higher score = better outcome. Best score=120. Worst score=0.\n\nTotal Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. Higher score = better outcome. Best score=13. Worst score=0.\n\nTotal integrated cUHDRS scale range: -7.6 to 24.8. The higher, the better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":"0.109"},{"groupId":"OG001","value":"-0.88","spread":"0.108"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in cUHDRS Total Score - Patients Off ADMs (mITT)","description":"The composite Unified Huntington Disease Rating Scale (cUHDRS) assesses 4 components (see secondary outcome for details):\n\nTotal Motor Score (TMS) for motor features. Higher score = worse outcome. Worst = 124.\n\nStroop Word Reading (SWR) measures attention and mental flexibility. Higher score = better outcome.\n\nSymbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Higher score = better outcome.\n\nTotal Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. The higher, the better.\n\nTotal cUHDRS scale range: -7.6 to 24.8 (assuming 150 as the max score of SWR). The higher, the better.\n\nThis sensitivity analysis was performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.114"},{"groupId":"OG001","value":"-0.31","spread":"0.108"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.130"},{"groupId":"OG001","value":"-0.34","spread":"0.125"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.140"},{"groupId":"OG001","value":"-0.48","spread":"0.135"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.143"},{"groupId":"OG001","value":"-0.53","spread":"0.137"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"0.159"},{"groupId":"OG001","value":"-0.54","spread":"0.158"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Q-Motor Finger Tapping Inter-Onset Interval (IOI) Mean - Patients Off ADMs (mITT)","description":"Quantitative (Q)-motor is a clinical assessment of fine motor skills. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. The index finger is positioned above a force transducer and is to tap as fast as possible. The start was defined as a rise of the force by 0.05 Newton above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. The IOI refers to the time between the onset of consecutive taps (the faster, the better).\n\nIn addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.85","spread":"6.846"},{"groupId":"OG001","value":"6.30","spread":"6.449"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.37","spread":"7.135"},{"groupId":"OG001","value":"11.95","spread":"6.792"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"7.365"},{"groupId":"OG001","value":"23.93","spread":"7.028"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"7.444"},{"groupId":"OG001","value":"24.36","spread":"7.230"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Q-Motor Pronation/Supination Inter-Tap-Interval (ITI) Mean - Patients Off ADMs (mITT)","description":"Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assesses the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is ITI (the faster, the better).\n\nIn addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.63","spread":"8.029"},{"groupId":"OG001","value":"20.43","spread":"7.448"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"9.124"},{"groupId":"OG001","value":"20.07","spread":"8.555"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.64","spread":"8.380"},{"groupId":"OG001","value":"28.55","spread":"7.867"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.73","spread":"9.740"},{"groupId":"OG001","value":"34.97","spread":"9.412"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Q-Motor Pronation/Supination Inter-Onset-Interval (IOI) Mean - Patients Off ADMs (mITT)","description":"Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assess the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is IOI (the faster, the better).\n\nIn addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.70","spread":"9.399"},{"groupId":"OG001","value":"13.68","spread":"8.829"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.40","spread":"10.978"},{"groupId":"OG001","value":"24.23","spread":"10.467"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.34","spread":"10.730"},{"groupId":"OG001","value":"30.13","spread":"10.232"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.21","spread":"12.702"},{"groupId":"OG001","value":"41.93","spread":"12.435"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in the UHDRS TFC Score - Patients Off ADMs (mITT)","description":"Total Functional Capacity (TFC) tests the capacity to maintain domestic chores, activities of daily living, finances, care level, and occupation. Scores from 0 - 13. Higher score = better outcome.\n\nIn addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.131"},{"groupId":"OG001","value":"-0.23","spread":"0.124"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.137"},{"groupId":"OG001","value":"-0.31","spread":"0.131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.149"},{"groupId":"OG001","value":"-0.45","spread":"0.143"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"0.156"},{"groupId":"OG001","value":"-0.54","spread":"0.150"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"0.166"},{"groupId":"OG001","value":"-0.54","spread":"0.163"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Stroop Word Reading (SWR) - Patients Off ADMs (mITT)","description":"Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome.\n\nIn addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"0.964"},{"groupId":"OG001","value":"-0.82","spread":"0.916"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":"1.100"},{"groupId":"OG001","value":"-0.04","spread":"1.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":"1.078"},{"groupId":"OG001","value":"-0.32","spread":"1.039"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"1.243"},{"groupId":"OG001","value":"-0.94","spread":"1.193"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"1.261"},{"groupId":"OG001","value":"-1.08","spread":"1.249"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Symbol Digit Modalities Test (SDMT) - Patients Off ADMs (mITT)","description":"Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to write match numbers with symbols. Scoring sums correct substitutions in 90 second interval (max = 110). Higher score = better outcome.\n\nIn addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.521"},{"groupId":"OG001","value":"-0.47","spread":"0.484"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"0.512"},{"groupId":"OG001","value":"-0.06","spread":"0.478"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"0.578"},{"groupId":"OG001","value":"-0.33","spread":"0.543"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.616"},{"groupId":"OG001","value":"0.07","spread":"0.576"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.617"},{"groupId":"OG001","value":"-0.36","spread":"0.598"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Total Motor Score (TMS) - Patients Off ADMs (mITT)","description":"Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Each rated 0 (normal) - 4 (abnormal). Higher score = worse outcome. Worst = 124.\n\nIn addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.568"},{"groupId":"OG001","value":"-0.03","spread":"0.530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.780"},{"groupId":"OG001","value":"0.96","spread":"0.729"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.766"},{"groupId":"OG001","value":"0.80","spread":"0.720"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"0.847"},{"groupId":"OG001","value":"1.28","spread":"0.790"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":"0.954"},{"groupId":"OG001","value":"1.63","spread":"0.916"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":250},"commonTop":["COVID-19","Fall","Diarrhea","Headache","Depression"]}}}